Zinger Key Points
- Adial secured a new U.S. patent expanding methods for identifying genetic markers linked to substance use disorders and AD04 treatment.
- The company completed a pharmacokinetics study confirming AD04’s bioavailability, dose proportionality, and safety profile.
- Get access to your new suite of high-powered trading tools, including real-time stock ratings, insider trades, and government trading signals.
On Wednesday, Adial Pharmaceuticals, Inc. ADIL announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark Office.
The patent expands the covered methods of identifying patients with specific genetic markers linked to substance use disorders and treating them with AD04, the company's investigational new drug product.
The treatment approach involves detecting the TT genotype of rs1042173 in the serotonin transporter gene (SLC6A4) and administering AD04.
These treatment methods are tailored for individuals suffering from disorders such as opioid dependence, opioid abuse, alcohol dependence, and other related conditions.
In December, Adial Pharmaceuticals announced that patent number 12150931 was issued by the United States Patent and Trademark Office on November 26, expanding the company's intellectual property coverage.
The patent covers a broader range of genotype combinations identified by the company's proprietary genetic diagnostic for targeted treatment of alcohol use disorder (AUD) with AD04, the company's lead investigational new drug product.
In October 2024, Adial Pharmaceuticals announced that the United States Patent and Trademark Office issued a Notice of Allowance for a new patent.
The patent, once issued, will expand Adial's intellectual property protection around its lead investigational drug, AD04, which is designed to treat alcohol use disorder.
In January, Adial Pharmaceuticals completed the AD04-103 pharmacokinetics (PK) study for AD04, confirming predictable bioavailability, dose proportionality, no food effect, and a safety profile consistent with ondansetron's use.
These results enable an End-of-Phase 2 FDA interaction to finalize the Phase 3 trial design and support ongoing partnership discussions.
Price Action: ADIL stock closed at $0.78 on Tuesday.
Read Next:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
